Cisplatin target
WebNov 23, 2024 · Cisplatin is the first-line chemotherapy agent for head and neck cancer (HNC), but its therapeutic effects are hampered by its resistance. In this study, we … WebNov 29, 2024 · Thus, pemetrexed and cisplatin target reciprocal lung cancer subpopulations, which could explain the increased efficacy of the combination therapy in …
Cisplatin target
Did you know?
Web2 days ago · Regarding platinum (IV) compounds, the focus was on complexes with biologically active ancillary ligands that exert a synergistic effect with platinum (II)-active complexes upon reduction, or those for which controllable activation can be realized thanks to intracellular stimuli. The compound cis-[Pt(NH3)2Cl2] was first described by Italian chemist Michele Peyrone in 1845, and known for a long time as Peyrone's salt. The structure was deduced by Alfred Werner in 1893. In 1965, Barnett Rosenberg, Van Camp et al. of Michigan State University discovered that electrolysis of platinum electrodes generated a soluble platinum complex which inhibited binary fission in Escherichia coli (E. coli) bacteria. Although bacterial cell growth continued, cell division …
WebCisplatin is a chemotherapy drug which is used to treat cancers including: sarcoma, small cell lung cancer, germ cell tumors, lymphoma, and ovarian cancer. While it is often … WebCisplatin is a chemotherapeutic drug that has been used in the treatment of various types of human cancers such as ovarian, lung, head and neck, testicular and bladder. Cisplatin …
WebWe found that miR-195-5p might play a role as an oncogene in LC cells and have an inhibitory effect on chemotherapy resistance to cisplatin. Afterward, by target gene … WebSep 26, 2014 · Abstract The objectives of this study were to identify specific long noncoding RNAs (lncRNAs) in laryngeal squamous cell carcinoma (LSCC) and to clarify the function of cisplatin and paclitaxel on the confirmed laryngeal cancer lncRNAs. Fifty-four pairs of laryngeal tumor and adjacent normal tissue were collected.
WebThe drug can be administered to hemodialysis (HD) patients to achieve an AUC of 4–6 such that carboplatin dose (mg)=Target AUCx25. The drug is not avidly protein bound shortly after administration, and approximately 70% is cleared by HD if performed within several hours after in- fusion (15).
National Center for Biotechnology Information www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov irm state law conversionWebApr 14, 2024 · Among the extracellular vesicles, apoptotic bodies (ABs) are only formed during the apoptosis and perform a relevant role in the pathogenesis of different diseases. Recently, it has been demonstrated that ABs from human renal proximal tubular HK-2 cells, either induced by cisplatin or by UV light, can lead to further apoptotic death in … irm ste catherine avignonWebCisplatin (DDP) is a common therapeutic option for non-small cell lung carcinoma (NSCLC). However, some patients fail to respond to the DDP chemotherapy. Therefore, identifying … irm st amand montrondWebThe cellular uptake of cisplatin and its targets. Reprinted with permission. 1. As seen in Figure 1, once inside the cell, cisplatin has a number of possible targets: DNA; RNA; … port hope remediationWeb2 days ago · In addition to genes already known for cisplatin resistance, to our surprise we found the gene NAE1, the regulator of the neddylation cascade," says first author Kai Funke, a Ph.D. student of Prof ... irm steam facebookWebOct 2, 2024 · Cisplatin is a platinum compound which is widely used in the treatment of various solid tumors including ovarian cancer. Up to now, the mechanism of cisplatin resistance in ovarian cancer is unclear. irm statute of limitationsWebFeb 16, 2024 · severe or ongoing nausea and vomiting; vision problems, pain behind your eyes; hearing problems, ringing in your ears; pain, redness, swelling, or skin changes … irm st germain en laye